Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.92 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | MAOA | P21397 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615238 | 1.00 | CD274 (0.92) | CD274EPHX2SMN1; SMN2ALDH1A1HTR1A | |
| SCHEMBL6569882 | 0.87 | CD274 (0.77) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| SCHEMBL4488493 | 0.87 | CD274 (0.77) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| SCHEMBL11479065 | 0.86 | CD274 (0.93) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| Moclobemide SCHEMBL3408310 | 0.86 | CD274 (1.00) | CD274EPHX2SMN1; SMN2ALDH1A1HTR1A | |
| SCHEMBL3543817 | 0.86 | CD274 (0.92) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| SCHEMBL280240 | 0.86 | MEN1 (0.76) | CD274ALDH1A1HTR1AMAOAMAOB | |
| SCHEMBL6034019 | 0.86 | TSHR (0.85) | CD274EPHX2ALDH1A1HTR1AMAOA | |
| Moclobemide SCHEMBL49708 | 0.86 | CD274 (1.00) | CD274EPHX2SMN1; SMN2ALDH1A1HTR1A | |
| SCHEMBL1512746 | 0.86 | CD274 (0.75) | CD274EPHX2ALDH1A1HTR1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005693-A | Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis | 河南中医药大学 | 2026-05-12 | — | — | CN | claimed |
| US-20020032197-A1 | Methods and compositions for using moclobemide | VELA PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2000006138-A2 | USE OF MOCLOBEMIDE FOR TREATING PAIN AND OTHER DISEASES | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-4210754-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1980-07-01 | — | — | US | claimed |
| CN-122005693-A | Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis | 河南中医药大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-04-19 | — | — | US | disclosed |
| WO-2010081036-A2 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20020032197-A1 | Methods and compositions for using moclobemide | VELA PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2000006140-A2 | USE OF MOCLOBEMIDE FOR TREATING CERTAIN PHSYCHIATRIC AND MEDICAL DISORDERS | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006139-A2 | USE OF MOCLOBEMIDE AND METABOLITES FOR TREATING AND PREVENTING SUBSTANCE ABUSE | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006138-A2 | USE OF MOCLOBEMIDE FOR TREATING PAIN AND OTHER DISEASES | VELA PHARMACEUTICALS INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| US-4210754-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032197-A1 | Methods and compositions for using moclobemide | FKBP5, FKBP1B, FKBP3 | CD274 2615/4885EPHX2 3022/4885SMN1; SMN2 1223/4885 |
| US-20120095217-A1 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | FLI1, CDC73, FOS | CD274 4742/4885EPHX2 1901/4885SMN1; SMN2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.